GILD icon

Gilead Sciences

112.05 USD
+2.75
2.52%
At close Jun 12, 4:00 PM EDT
After hours
111.77
-0.28
0.25%
1 day
2.52%
5 days
0.32%
1 month
7.93%
3 months
-1.70%
6 months
21.29%
Year to date
21.95%
1 year
74.15%
5 years
53.07%
10 years
-4.77%
 

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,600

0
Funds holding %
of 7,295 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

149% more first-time investments, than exits

New positions opened: 274 | Existing positions closed: 110

79% more funds holding in top 10

Funds holding in top 10: 28 [Q4 2024] → 50 (+22) [Q1 2025]

18% more capital invested

Capital invested by funds: $98.3B [Q4 2024] → $116B (+$18B) [Q1 2025]

6% more funds holding

Funds holding: 1,852 [Q4 2024] → 1,965 (+113) [Q1 2025]

0% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $1.19B

1.79% less ownership

Funds ownership: 85.16% [Q4 2024] → 83.37% (-1.79%) [Q1 2025]

17% less repeat investments, than reductions

Existing positions increased: 672 | Existing positions reduced: 806

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$117
4%
upside
Avg. target
$125
12%
upside
High target
$135
20%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Mizuho
Salim Syed
4%upside
$117
Outperform
Maintained
5 May 2025
Oppenheimer
Hartaj Singh
12%upside
$125
Outperform
Maintained
25 Apr 2025
Morgan Stanley
Matthew Harrison
20%upside
$135
Overweight
Maintained
25 Apr 2025
Cantor Fitzgerald
Carter Gould
12%upside
$125
Overweight
Assumed
22 Apr 2025
BMO Capital
Evan Seigerman
7%upside
$120
Outperform
Maintained
17 Apr 2025

Financial journalist opinion

Based on 36 articles about GILD published over the past 30 days

Neutral
Accesswire
10 hours ago
ATTENTION GILD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
ATTENTION GILD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
Neutral
Accesswire
11 hours ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out
Positive
Zacks Investment Research
13 hours ago
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Neutral
Accesswire
1 day ago
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD)
Neutral
Accesswire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Negative
Zacks Investment Research
1 day ago
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Positive
Zacks Investment Research
1 day ago
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Negative
The Motley Fool
2 days ago
Why Gilead Scinces Stock Tumbled on Tuesday
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (GILD -2.54%) took some hits on Tuesday. Investors traded it down by more than 2%, comparing unfavorably to the 0.6% gain of the benchmark S&P 500 (^GSPC 0.55%).
Why Gilead Scinces Stock Tumbled on Tuesday
Neutral
Seeking Alpha
2 days ago
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Negative
Proactive Investors
2 days ago
Gilead shares fall after FDA places clinical hold on HIV treatment trials
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug Administration (FDA) has placed clinical holds on studies involving two of the company's investigational HIV drugs. The FDA's clinical hold affects trials of GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor.
Gilead shares fall after FDA places clinical hold on HIV treatment trials
Charts implemented using Lightweight Charts™